Skip to content

#礼来

Today 0 items
Oct 14Wed
  1. nature.com46

    Can GLP-1s heal the brain? Obesity drugs get a makeover for addiction and depression

    Eli Lilly presented the first clinical results of brenipatide, a GLP-1 and GIP mimic related to tirzepatide, for alcohol use disorder at the Psych Congress in New Orleans; its half-life is 9–12 days versus 5–7 days for approved GLP-1 drugs. Kariya Pharmaceuticals shared early clinical results of the GLP-1 compound KP405 for Parkinson's disease, and Baseline Therapeutics plans phase III trials of BT-001 for alcohol use disorder starting in early 2027. Academic trials, including a 2025 semaglutide study in alcohol use disorder, have shown reduced craving and heavy drinking, encouraging industry interest in GLP-1 therapies for addiction and other brain disorders.

Oct 12Mon
  1. biopharmadive.com56

    Pharma’s $500B patent problem will come in waves — not as a cliff

    Evaluate forecasting data from Norstella show more than $500 billion in worldwide prescription drug sales at risk from generic competition between 2026 and 2032, with the largest single-year exposure of $158 billion in 2031. Merck is most exposed near term as Keytruda nears expiry in 2028, a year with $99 billion in sales at risk, while AbbVie faces roughly $50 billion of exposure in 2032 when Rinvoq and Skyrizi lose protection. Patent-exposed companies have responded with dealmaking since the start of 2024, led by Merck's six deals totalling $30.9 billion and Lilly's $27.2 billion across nine.

    Why it matters: Quantifies the multiyear patent-expiry risk facing major drugmakers and the dealmaking it is already driving.

Oct 9Fri
  1. biospace.com54

    TRexBio, Retension raise $161.7M in IPOs; City, Iambic set proposed offering terms

    TRexBio raised $116.7 million in its Nasdaq IPO, selling 8.3 million shares at $14 to fund TRB-061, a fusion protein in early-stage development for atopic dermatitis with a Phase 1b topline readout expected mid-2027. Retension Pharmaceuticals raised $45 million at $12 per share to advance RTN-001, a PDE-5 blocker for hypertension, through Phase 2b and into Phase 3. City Therapeutics expects about $158.3 million and Iambic Therapeutics about $135 million from upcoming offerings.

    Why it matters: Four biotech IPOs in one week signal a reopening of the public markets for drug developers.

  2. biopharmadive.com61

    TRex Bio prices $117M IPO to support immune drug work

    TRex Bio priced a $117 million IPO, selling 8,333,334 shares at $14 each, and begins trading Friday on Nasdaq under "TRXB." The company is developing Treg-activating drugs for immunological conditions, including TRB-061, in a Phase 1 trial with topline data expected in 2027, and TRB-071 for inflammatory bowel disease, which could enter testing next year. Eli Lilly, TRex's largest equity holder at about 24% pre-IPO, and Johnson & Johnson have licensed or optioned treatments discovered by TRex, which has raised $220 million in venture financing to date.

    Why it matters: IPO shows continued investor appetite for immune-focused biotechs, with six of 23 drug developers going public in 2026 working on immune diseases.

Oct 7Wed
  1. biospace.com69

    Biotech VC Forbion raises record $2.6B to support 30 ‘high-potential’ companies

    Forbion has raised €2.3 billion ($2.6 billion) across two new funds, Growth Opportunities Fund IV and Ventures Fund VIII, its largest raise ever, to back some 30 high-potential drugmakers, from pre-clinical and early clinical-stage biotechs to private growth, crossover and public investments. Eli Lilly participated alongside KfW Capital, PGM and Kauffman Foundation. The Dutch firm now has approximately €7.5 billion ($8.42 billion) in assets under management across a portfolio of more than 140 companies.

    Why it matters: One of the largest life sciences VC raises in five years signals where biotech capital is flowing.

  2. biospace.com40

    Genmab and AbbVie’s Epkinly win, a rush of deals, Sarepta’s turnaround hopes, more

    Genmab and AbbVie's bispecific antibody Epkinly, approved in May 2023 for diffuse large B cell lymphoma after at least two prior systemic lines, cut risk of disease progression or death by 51% in a Phase 3 trial when combined with R-CHOP in the frontline setting. In deals, Shionogi bought IntraBio for $2 billion, Novartis committed up to $7.8 billion to Abogen Biosciences, Eli Lilly added up to $870 million with Gate Bioscience, and Sanofi and Regeneron renewed their collaboration with a $1 billion upfront. Sarepta shared Elevidys data in older Duchenne patients at the World Muscle Society meeting, with Jefferies citing upcoming readouts and an FDA decision on Amondys 45 and Vyondys 53.

  3. biopharmadive.com60

    Forbion, a prominent biotech investor, raises $2.6B for a pair of venture funds

    Forbion, a Netherlands-based venture firm focused on life sciences, raised 2.3 billion euros ($2.6 billion) across two funds, Forbion Growth Opportunities IV and Forbion Ventures Fund VIII, its largest fundraise to date. The funds have capacity to invest in as many as 30 young companies; recent investments include Sling Therapeutics and Solstice Oncology. Backers include MN, PGGM, the Kauffman Foundation, KfW Capital and Eli Lilly, and Forbion now has 7.5 billion euros under management.

    Why it matters: Europe's largest life sciences venture fund raised its biggest sum yet while European biotech faces declining investment and clinical trial activity.

Oct 6Tue
  1. biospace.com46

    Compliance concerns hinder rollout of AI in drug manufacturing: Survey

    Fewer than 10% of drugmakers are scaling AI in clinical or commercial manufacturing, according to a CRB survey of more than 400 R&D and manufacturing professionals for its 2026 Horizons report. Use is concentrated in nonregulated areas such as administrative workflows (56%) and drug discovery (45%), with accuracy and quality concerns and insufficient validation standards cited as the main barriers. CRB found that 31% of respondents plan to use AI in regulated manufacturing within three years, and another 31% are considering it without a formal plan.

    Why it matters: Shows regulatory and validation concerns are blocking AI adoption in drug manufacturing, with an FDA warning letter already issued.

Oct 5Mon
  1. biospace.com60

    Lilly doubles down on Gate alliance to unlock new drug class with another $870M+ in biobucks

    Eli Lilly has expanded its alliance with Gate Bioscience in a deal worth up to more than $870 million, adding one new target with the option of a second to their existing collaboration on Gate's Molecular Gate discovery engine for difficult-to-drug extracellular proteins. Gate, which signed an initial deal with Lilly worth up to $856 million in July 2025, will receive an undisclosed upfront payment plus payments on preclinical, clinical and commercial milestones and tiered royalties. Gate leads discovery while Lilly takes an exclusive worldwide license and handles development from later-stage preclinical work through commercialization; no indications have been disclosed.

    Why it matters: Lilly is committing another $870 million to Gate's Molecular Gate platform, deepening a fast-repeat collaboration on a new drug class.

  2. biopharmadive.com40

    Optogenetics researchers win a Nobel Prize; Roche bets on Alector brain drug

    The Nobel Prize in Physiology or Medicine went to Peter Hegemann, Georg Nagel and Karl Deisseroth for optogenetics, a light-based method for studying neurons. Alector licensed its preclinical Parkinson's therapy AL050 to Roche's Genentech for $100 million in guaranteed cash and up to $1.17 billion in milestones plus royalties. Separately, the FDA approved Lilly's Jaypirca as a first-line treatment for CLL or SLL patients without a 17p deletion.

    Why it matters: Nobel recognition for optogenetics and a sizeable Roche-Alector brain drug deal matter to neuroscience-focused readers.

  3. statnews.com43

    STAT+: Lilly’s Jaypirca approved as first-line CLL therapy

    The FDA has approved Eli Lilly's Jaypirca as a first-line therapy for chronic lymphocytic leukemia (CLL), according to STAT News. The approval moves Jaypirca, already known in CLL treatment discussions, into the earlier-line setting. Details of the decision are behind the STAT+ paywall, with further coverage available to subscribers.

    Why it matters: First-line CLL approval expands the eligible patient population for Lilly's Jaypirca.

  4. nature.com75

    COPD trial wins spur broad respiratory hopes

    AstraZeneca's tozorakimab, an IL-33-targeted antibody, reduced COPD exacerbations by up to 30% in current and former smokers in two trials, with an FDA decision expected in the first quarter of 2027. Unlike dupilumab and mepolizumab, it worked across patients with all blood eosinophil counts, addressing non-eosinophilic COPD. The success, after mixed results for other IL-33 agents like itepekimab, is reviving industry interest in IL-33 and alarmin targets across respiratory disease.

    Why it matters: First IL-33 win in COPD works regardless of eosinophil count, reshaping the inflammatory biologic landscape.

Oct 3Sat
  1. fda.gov74

    FDA approves pirtobrutinib for previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma

    FDA approved Eli Lilly's pirtobrutinib (Jaypirca) on October 2, 2026 for adults with previously untreated CLL or SLL without 17p deletion. In the BRUIN CLL-313 trial of 282 patients randomized to pirtobrutinib or bendamustine plus rituximab, median PFS was not estimable with pirtobrutinib versus 33.5 months in the control arm (hazard ratio 0.20, p<0.0001) at a median follow-up of 28 months. The recommended dose is 200 mg orally once daily until progression or unacceptable toxicity.

    Why it matters: FDA approval of pirtobrutinib moves the BTK inhibitor into first-line CLL/SLL treatment based on a 0.20 hazard ratio.

Oct 2Fri
  1. Lancet71

    Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial.

    Orforglipron, an oral non-peptide GLP-1 receptor agonist, was non-inferior to insulin glargine for four-component major adverse cardiovascular events in 2749 adults with type 2 diabetes at increased cardiovascular risk: MACE-4 occurred in 57 (4·2%) of 1358 orforglipron participants versus 67 (5·0%) of 1343 insulin glargine participants (HR 0·84; 95% CI 0·59-1·20) over a median follow-up of 2 years. Clinically significant or severe hypoglycaemia was less frequent with orforglipron (93, 6·8%) than insulin glargine (260, 19·2%), while gastrointestinal adverse events were more frequent (62·1% vs 14·2%). The results establish cardiovascular safety for a non-peptide GLP-1 receptor agonist, a class not previously studied for this outcome.

    Why it matters: First cardiovascular safety data for an oral non-peptide GLP-1 receptor agonist, a class not previously studied for cardiovascular outcomes.

Oct 1Thu
  2. biospace.com54

    Foghorn lays off 40% of staff after Lilly collaboration ends

    Foghorn Therapeutics and Eli Lilly ended their oncology collaboration after Phase 1 data on cancer candidate FHD-909 (LY4050784) showed insufficient efficacy, halting its move into clinical development expansion and a SMARCA2 degrader program. Foghorn is cutting about 40% of its workforce, leaving roughly 65 full-time employees, and will refocus on its proprietary programs including EP300 and CBP degraders. The 2021 deal had brought $300 million upfront plus an $80 million equity investment from Lilly's Loxo Oncology, and the changes should extend Foghorn's cash runway into the second half of 2029.

    Why it matters: A terminated big-pharma oncology alliance triggers pipeline reprioritization, layoffs and a readout on the SMARCA2 synthetic lethality hypothesis.

  3. N Engl J Med82

    Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity.

    Once-weekly retatrutide produced mean body-weight reductions of 17.6%, 23.7%, and 25.0% at 4, 9, and 12 mg over 80 weeks in 2339 adults with obesity without diabetes, versus 3.9% with placebo. In subgroups, WOMAC pain fell 3.5 and 3.6 points at 9 and 12 mg versus 1.9 with placebo in 574 participants with knee osteoarthritis, and apnea-hypopnea events per hour fell 34.3 and 31.7 versus 9.9 in 243 participants with obstructive sleep apnea. The phase 3 results extend triple-receptor agonist efficacy beyond weight to obesity-related pain and sleep outcomes.

    Why it matters: Phase 3 data show retatrutide's weight loss and benefits in knee osteoarthritis pain and obstructive sleep apnea.

  4. Lancet73

    Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial.

    Once-weekly retatrutide produced dose-dependent weight loss in adults with obesity and type 2 diabetes over 80 weeks: mean bodyweight change was -16·8% with 9 mg and -18·8% with 12 mg versus -5·1% with placebo. In the phase 3 TRIUMPH-2 trial of 1152 participants, gastrointestinal adverse events were the most frequent, and discontinuation due to adverse events or death was higher with 9 mg and 12 mg than with placebo. The findings support retatrutide as a treatment option for obesity in people with type 2 diabetes.

    Why it matters: Phase 3 data show triple-agonist retatrutide achieves up to -18·8% bodyweight change in obesity with type 2 diabetes.

  5. nature.com56

    Restoring hearing in people with a rare form of deafness

    A gene therapy delivering a functional OTOF gene to inner-ear hair cells improved hearing in around 80% of participants within 24 weeks in the CHORD clinical trial, which enrolled 24 participants aged between 10 months and 16 years with OTOF-associated hearing impairment. Each participant received Otarmeni as a one-time infusion, either in one ear or in both ears. In April, Otarmeni became the first gene therapy for hearing loss approved by the US Food and Drug Administration.

Sep 24Thu
  1. fiercebiotech.com42

    Lilly puts up $100M, plus billions on the backend, to form 5-target deal with China's InnoCare

    Eli Lilly will pay InnoCare Pharma $100 million in upfront and near-term payments for a five-target drug discovery collaboration, with up to $3.25 billion in potential milestones plus single-digit tiered royalties on net sales. Beijing-based InnoCare will apply its drug discovery platform to targets the partners have not disclosed, beyond saying the programs address critical unmet medical needs. The deal extends a Lilly deal spree funded by GLP-1 cash.

    Why it matters: Large China-US discovery pact shows Lilly continuing its GLP-1-funded deal spree.

Sep 22Tue
  1. STAT News43

    STAT+: Lilly’s breast cancer combo wins approval

    The FDA approved Eli Lilly's combination drug treatment for patients with an advanced form of breast cancer, reported Sept. 21, 2026. The decision gives Lilly a new option in the advanced breast cancer setting. Full details of the approval are available to STAT+ subscribers.

    Why it matters: FDA approval of a Lilly combination therapy for advanced breast cancer directly affects oncology treatment options.

Sep 9Wed
  1. statnews.com47

    STAT+: Leukemia drug data suggested a different way to treat diabetes. A new biotech will test that idea

    Kura Oncology is spinning off its menin inhibitor programme into a new company, Caspian Therapeutics, which launches with $50 million in financing led by BVF Partners and joined by Eli Lilly. Animal studies of Kura's menin-targeting leukemia therapy showed the approach also helped control blood sugar, so Caspian will develop menin inhibitors for diabetes and other cardiometabolic diseases, taking its lead small molecule into an early-phase diabetes trial and backing a second candidate. Kura retains about 50% ownership, Kura CEO Troy Wilson becomes executive chair, and Robert Spencer was named to lead Caspian.

    Why it matters: A leukemia-derived menin inhibitor programme enters diabetes via a $50 million spinout with Eli Lilly involvement.

Sep 1Tue
  1. biocentury.com55

    Lilly’s deal spree continues with Merida takeout: Deals Report

    Eli Lilly has agreed to acquire Merida Biosciences, a four-year-old Cambridge, Massachusetts autoimmunity and allergy biotech, in a deal valued at up to $2.88 billion. The acquisition gives Lilly MER511, a Phase I Fc therapeutic that binds anti-TSHR autoantibodies for Graves' disease and thyroid eye disease. Merida raised a $121 million series A in 2025 co-led by Bain Capital Life Sciences, BVF Partners and Third Rock Ventures.

    Why it matters: Lilly's thirteenth takeout expands its autoimmune pipeline into Graves' disease and thyroid eye disease.

Aug 31Mon
Aug 28Fri
  1. FiercePharma65

    Lilly scores Novo-pressuring Mounjaro expansion to curb heart risks in diabetes patients

    Eli Lilly has won FDA approval for Mounjaro to reduce the risk of heart attack or stroke in at-risk adults with type 2 diabetes. The decision adds a cardiovascular risk reduction use to the drug as Lilly competes with Novo Nordisk in diabetes and obesity. Lilly secured the approval on Friday.

    Why it matters: FDA approval extends Mounjaro's use to cardiovascular risk reduction in type 2 diabetes, intensifying competition with Novo Nordisk.

Aug 23Sun
  1. N Engl J Med88

    Selpercatinib in Early-Stage RET Fusion-Positive Non-Small-Cell Lung Cancer.

    Adjuvant selpercatinib for up to 3 years after definitive therapy sharply reduced recurrence in RET fusion-positive NSCLC. In the 109 patients with stage II or IIIA disease, 2-year investigator-assessed event-free survival was 92% with selpercatinib versus 61% with placebo (hazard ratio 0.17; P<0.001), and blinded independent central review was consistent. The findings extend selpercatinib from advanced disease into the early-stage, curative-intent setting.

    Why it matters: First phase 3 evidence that a RET inhibitor works as adjuvant therapy in early-stage NSCLC.

Aug 20Thu
  1. fiercepharma.com59

    Lilly’s long-acting insulin wins NICE blessing ahead of potential UK approval

    NICE has recommended Eli Lilly's once-weekly insulin Onswik for NHS coverage in Type 2 diabetes, based on the QWINT-1, QWINT-3 and QWINT-4 trials, which showed non-inferior A1C reduction and similar safety versus daily insulins degludec and glargine. Hundreds of thousands of UK patients could cut annual injections by 85% if approved. Lilly awaits MHRA marketing authorization, with an FDA decision possible by year-end and a CHMP opinion already secured pending European Commission sign-off.

Aug 18Tue
  1. biocentury.com40

    Slate, Redx to reach NASDAQ via reverse mergers: Deals Report

    Slate and Redx plan to reach NASDAQ through reverse mergers with shell companies, a route private biotechs continue to use as available shells pair with venture-backed start-ups. Syndicates have in many cases provided nine-digit sums in concurrent placements, letting companies list and raise cash without a traditional IPO. Separately, bankrupt Sangamo's assets go to Lilly and PTC.

Aug 17Mon
  1. BMJ58

    Tirzepatide and the risk of atherosclerotic cardiovascular events: population based cohort study.

    Adding tirzepatide to standard care cut one-year MACE risk from 4.4% to 2.9% versus sitagliptin in 52,971 adults with type 2 diabetes and established atherosclerotic cardiovascular disease (hazard ratio 0.68, NNT=70). Myocardial infarction fell (HR 0.67), ischaemic stroke did not. Infections requiring admission and infection related mortality were also lower, and negative control outcomes showed no association.

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org